212.85 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||211.86 x 200|
|Ask||212.98 x 100|
|Day's Range||211.90 - 213.79|
|52 Week Range||65.54 - 213.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||184.33|
AveXis, Inc. (AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first patient has been dosed in a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3 (SPRINT). “Treating SMA as early as possible is critically important in order to rescue motor neurons before they are permanently lost. SPRINT enables us to understand how intervening in pre-symptomatic infants with AVXS-101 may impact clinical outcomes, including milestone development such as functional sitting, standing without support and walking,” said Dr. Sukumar Nagendran, Chief Medical Officer of AveXis.
–A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial–. –All patients in the therapeutic dose cohort in the Phase 1 trial were alive and ...
NEW YORK , April 24, 2018 /PRNewswire/ -- ADT Inc. (ADT) Lifshitz & Miller announces investigation into possible securities law violations in connection with ADT's IPO. If you are an ADT investor, and ...
The following statement is being issued by Levi & Korsinsky, LLP:
BERWYN, Pa. , April 19, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Swiss drugmaker Novartis' (NOVN.S) first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.
CHICAGO, April 19, 2018-- AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced ...
Nationwide Children’s Hospital made a huge leap in commercialization efforts in 2017: It executed 18 licenses or options on its technology, compared with 12 in 2012 and nine in each of the previous three years. The hospital launched four new companies – and made a record $36.7 million income on past licensing deals.
Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), ...
BALA CYNWYD, PA / ACCESSWIRE / April 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of AveXis, Inc. ("AveXis" ...
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
GlaxoSmithKline (GSK.L) is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.
Britain's Orchard Therapeutics, which has already raised more than $140 million (98.54 million pounds) to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines. Chief Executive Mark Rothera also told Reuters that an initial public offering (IPO) was an option beyond this next private financing move. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion acquisition of AveXis (AVXS.O) this week - but the rare disease products sold to Orchard are too niche for GSK as it refocuses its R&D efforts.